Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study

Journal of Neuroimmunology

Volumn 254, Issue 1-2, 2013, Pages 131-140

  Dhib Jalbut, Suhayl ^a   Sumandeep, Sumandeep ^a   Valenzuela, Reuben ^a   Ito, Kouichi ^a   Patel, Payal ^b   Rametta, Mark ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

Cytokines; Immune markers; Interferon beta 1b; Multiple sclerosis

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; CXCR3+ CD8+ T LYMPHOCYTE; DISABILITY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG RESPONSE; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SCORING SYSTEM; T LYMPHOCYTE; TREATMENT DURATION;

ABORTION, HABITUAL; ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; CYTOKINES; DISABILITY EVALUATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-BETA; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MULTIPLE SCLEROSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT;

EID: 84871695430     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.08.012     Document Type: Article

References (43)

1. Alexander J.S., Harris M.K., Wells S.R., Mills G., Chalamidas K., Ganta V.C., McGee J., Jennings M.H., Gonzalez-Toledo E., Minagar A. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult. Scler. 2010, 16:801-809.
2. Axtell R.C., de Jong B.A., Boniface K., Van der V., Bhat R., De Sarno P., Naves R., Han M., Zhong F., Castellanos J.G., Mair R., Christakos A., Kolkowitz I., Katz L., Killestein J., Polman C.H., de Waal Malefyt R., Steinman L., Raman C. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 2010, 16:406-412.
3. Azoulay D., Mausner-Fainberg K., Urshansky N., Fahoum F., Karni A. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. J. Neuroimmunol. 2009, 211:114-119.
4. Bushnell S.E., Zhao Z., Stebbins C.C., Cadavid D., Buko A.M., Whalley E.T., et al. Serum IL-17F does not predict poor response to IM IFNbeta-1a in relapsing-remitting MS. Neurology 2012, 79:531-537.
5. Calabresi P.A., Tranquill L.R., Dambrosia J.M., Stone L.A., Maloni H., Bash C.N., Frank J.A., McFarland H.F. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann. Neurol. 1997, 41:669-674.
6. Candelario-Jalil E., Yang Y., Rosenberg G.A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009, 158:983-994.
7. Clerici M., Saresella M., Trabattoni D., Speciale L., Fossati S., Ruzzante S., Cavaretta R., Filippi M., Caputo D., Ferrante P. Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. J. Neuroimmunol. 2001, 121:88-101.
8. Codarri L., Gyulveszi G., Tosevski V., Hesske L., Fontana A., Magnenat L., Suter T., Becher B. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 2011, 12:560-567.
9. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernandez O., Hartung H., Seeldrayers P., Sorensen P.S., Rovaris M., Martinelli V., Hommes O.R. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001, 357:1576-1582.
10. Dhib-Jalbut S. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 2007, 68:S13-S21.
11. Dhib-Jalbut S., Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010, 74(Suppl. 1):S17-S24.
12. Garcia-Montojo M., Dominguez-Mozo M.I., De Las Heras V., Bartolome M., Garcia-Martinez A., Arroyo R., varez-Lafuente R. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study. Eur. J. Neurol. 2010, 17:470-478.
13. Goodin D.S., Frohman E.M., Garmany G.P., Halper J., Likosky W.H., Lublin F.D., Silberberg D.H., Stuart W.H., van den Noort S. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58:169-178.
14. Graber J., Zhan M., Ford D., Kursch F., Francis G., Bever C., Panitch H., Calabresi P.A., Dhib-Jalbut S. Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J. Neuroimmunol. 2005, 161:169-176.
15. Graber J.J., Ford D., Zhan M., Francis G., Panitch H., Dhib-Jalbut S. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J. Neuroimmunol. 2007, 185:168-174.
16. Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: relevance for repair strategies in multiple sclerosis?. J. Neurol. Sci. 2008, 265:93-96.
17. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., Simonian N.A., Slasor P.J., Sandrock A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 2000, 343:898-904.
18. Katz D., Taubenberger J.K., Cannella B., McFarlin D.E., Raine C.S., McFarland H.F. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann. Neurol. 1993, 34:661-669.
19. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13:1173-1175.
20. Killestein J., Polman C.H. Determinants of interferon beta efficacy in patients with multiple sclerosis. Nat. Rev. Neurol. 2011, 7:221-228.
21. Krakauer M., Sorensen P.S., Khademi M., Olsson T., Sellebjerg F. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. Scand. J. Immunol. 2006, 64:155-163.
22. Kurachi M., Kurachi J., Suenaga F., Tsukui T., Abe J., Ueha S., et al. Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration. J. Exp. Med. 2011, 208:1605-1620.
23. Leppert D., Waubant E., Burk M.R., Oksenberg J.R., Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 1996, 40:846-852.
24. Lindquist S., Hassinger S., Lindquist J.A., Sailer M. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment. Mult. Scler. 2011, 17:851-866.
25. Martin-Saavedra F.M., Gonzalez-Garcia C., Bravo B., Ballester S. Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol. Immunol. 2008, 45:4008-4019.
26. Mokhtarian F., Shi Y., Shirazian D., Morgante L., Miller A., Grob D. Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis. J. Immunol. 1994, 152:6003-6010.
27. Muraro P.A., Leist T., Bielekova B., McFarland H.F. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J. Neuroimmunol. 2000, 111:186-194.
28. Navikas V., Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J. Neurosci. Res. 1996, 45:322-333.
29. Ozenci V., Kouwenhoven M., Teleshova N., Pashenkov M., Fredrikson S., Link H. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J. Neuroimmunol. 2000, 108:236-243.
30. Pachner A.R., Cadavid D., Wolansky L., Skurnick J. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology 2009, 73:1485-1492.
31. Polman C.H., Bertolotto A., Deisenhammer F., Giovannoni G., Hartung H.P., Hemmer B., Killestein J., McFarland H.F., Oger J., Pachner A.R., Petkau J., Reder A.T., Reingold S.C., Schellekens H., Sorensen P.S. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010, 9:740-750.
32. Prod'homme T., Zamvil S.S. Bench to bedside: tempering antigen-presenting cells in multiple sclerosis. Nat. Med. 2008, 14:614-615.
33. Rohowsky-Kochan C., Molinaro D., Cook S.D. Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis. Mult. Scler. 2000, 6:69-77.
34. Rudick R.A., Goodkin D.E., Jacobs L.D., Cookfair D.L., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Granger C.V., Simon J.H., Alam J.J., Simonian N.A., Campion M.K., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E., Priore R.L., Whitham R.H., The Multiple Sclerosis Collaborative Research Group (MSCRG) Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997, 49:358-363.
35. Sarchielli P., Zaffaroni M., Floridi A., Greco L., Candeliere A., Mattioni A., Tenaglia S., Di Filippo M., Calabresi P. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Mult. Scler. 2007, 13:313-331.
36. Stone L.A., Smith M.E., Albert P.S., Bash C.N., Maloni H., Frank J.A., McFarland H.F. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. Neurology 1995, 45:1122-1126.
37. Stuve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., Yong V.W. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 1996, 40:853-863.
38. The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995, 45:1277-1285.
39. Waubant E., Goodkin D.E., Gee L., Bacchetti P., Sloan R., Stewart T., Andersson P.B., Stabler G., Miller K. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999, 53:1397-1401.
40. Wiesemann E., Deb M., Hemmer B., Radeke H.H., Windhagen A. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clin. Immunol. 2008, 128:306-313.
41. Yong V.W. Prospects of repair in multiple sclerosis. J. Neurol. Sci. 2009, 277(Suppl. 1):S16-S18.
42. Zhang G.X., Baker C.M., Kolson D.L., Rostami A.M. Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis. Mult. Scler. 2000, 6:3-13.
43. Zhang L., Yuan S., Cheng G., Guo B. Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. PLoS One 2011, 6:e28432.